Tobin Schilke - Jan 20, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Jan 20, 2023
Transactions value $
-$31,000
Form type
4
Date filed
1/23/2023, 04:35 PM
Previous filing
Jan 10, 2023
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale -$31K -1K -1.7% $31.00 57.9K Jan 20, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
F2 Includes 3,716 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan.